Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for screening diabetic nephropathy drugs in vitro

A technology for diabetic nephropathy and in vitro screening, applied in the field of screening diabetic nephropathy drugs, can solve the problems of high cost, unstable model, complicated operation, etc., and achieve the effect of simple and easy operation, avoiding ethical problems and good integration.

Active Publication Date: 2021-08-06
BEIJING HANDIAN PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The problems of using this model include: 1) high mortality rate of animals; 2) relatively mild renal lesions, less likely to form glomerulosclerosis, tubulointerstitial fibrosis and other renal pathological changes similar to human DN patients in the middle and late stages; 3) STZ has nephrotoxicity, which will interfere with the experimental results to a certain extent; 4) The severity of proteinuria is related to the dose of STZ
[0009] In summary, DN animal models generally have problems such as long modeling time, cumbersome operation, high cost, and unstable models.
For the drug screening and drug efficacy evaluation of DN new drug development, it takes at least half a year, costs hundreds of thousands to more than one million yuan, and there are many uncontrollable factors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for screening diabetic nephropathy drugs in vitro
  • A method for screening diabetic nephropathy drugs in vitro
  • A method for screening diabetic nephropathy drugs in vitro

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Screening experiment on the preparation process of astragalus gorgon rhubarb traditional Chinese medicine composition

[0050] The purpose of the experiment: to screen the optimal preparation process of the traditional Chinese medicine composition through the method of serum pharmacology, combined with the in vitro drug efficacy screening method of the present invention, so as to lay the foundation for subsequent research and development.

[0051] 1. Experimental materials

[0052] (1) Experimental animals

[0053] 30 SPF grade SD rats, 180-220g, were purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2014-0004, and were bred in Beijing Yizhuang International Biomedical Technology Co., Ltd., license number : SYXK (Beijing) 2015-0010.

[0054] (2) Experimental cells

[0055] Human renal tubular epithelial cells HKC were purchased from the Cell Resource Center of the Institute of Basic Medical Sciences, Chinese Academy of...

Embodiment 2

[0100] Embodiment 2 rhubarb preparation technology screening experiment

[0101] The results of Example 1 show that the drug effect of process 4 is better than that of process 3. The difference between process 4 and process 3 is only that the extraction solvent of rhubarb is different. In process 3, rhubarb is alcohol extraction, and in process 4, rhubarb is water extraction. In this experiment The glomerular mesangial cells and renal tubular epithelial cells most closely related to the onset of diabetic nephropathy were selected to test whether the water-extracted sample of rhubarb was more effective than the alcohol-extracted sample of rhubarb.

[0102] 1. Experimental materials

[0103] (1) Experimental animals

[0104] Animals 18 SPF grade SD rats, 180-220g, were purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2014-0004, and were raised in Beijing Yizhuang International Biomedical Technology Co., Ltd., license No.: SYXK (Beijing) ...

Embodiment 3

[0149] Example 3 Astragalus gorgon rhubarb traditional Chinese medicine composition process 3 and process 4 animal experiments

[0150] The results of Examples 1 and 2 show that Process 4 is superior to Process 3, and even better than Processes 1 and 2 in terms of inhibiting proliferation of renal intrinsic cells and increasing glucose intake under high glucose conditions. In order to further confirm the reliability of the proposed screening method, the in vivo animal experiment was conducted again through the type 1 SD rat DN model to test the conclusion of the in vitro cell screening test.

[0151] 1. Experimental materials

[0152] (1) Experimental animals

[0153] 57 SPF grade SD rats, 180-220g, were purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2014-0004, and were bred in Beijing Yizhuang International Biomedical Technology Co., Ltd., license number : SYXK (Beijing) 2015-0010.

[0154] (2) Experimental drugs

[0155] Prescrip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for in vitro screening of drugs for diabetic nephropathy by measuring the change of glucose concentration and the change of cell proliferation inhibition rate in the culture solution of unit cells of mesangial cells, renal tubular epithelial cells and endothelial cells after administration. method. The method is not only suitable for the screening of small molecular compounds, but also particularly suitable for the screening of prescription compatibility and preparation process screening of traditional Chinese medicine compositions. Applying this model and method to screen drugs is low in cost, short in time, easy to implement, and highly reliable, and is of great significance for the early screening of candidate drugs for diabetic nephropathy.

Description

technical field [0001] The invention relates to a method for screening drugs in vitro, which is mainly used for screening drugs for diabetic nephropathy. More specifically, the present invention relates to a method for screening diabetic nephropathy drugs in vitro using high-throughput means. Background technique [0002] Diabetic nephropathy (diabetic nephropathy, DN) is currently one of the most serious and common complications of diabetes. The blood vessels of patients are continuously in a state of high glucose, resulting in various microvascular diseases. The early manifestations of DN are renal extracellular matrix hyperplasia, glomerular hyperfiltration and renal tubular hyperperfusion. As the course of the disease progresses, it causes progressive loss of glomerulus and tubular cells, eventually leading to glomerulosclerosis, tubular atrophy, and renal interstitial fibrosis. Typical pathological manifestations are: increased proteinuria; a transient increase in glo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/02C12Q1/26C12Q1/28C12Q1/54
CPCC12Q1/26C12Q1/28C12Q1/54G01N33/5044G01N2800/347
Inventor 林德良蒿长英钟云黄卉
Owner BEIJING HANDIAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com